These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 36369033)

  • 21. Circulating tumor cells expressing cancer stem cell marker CD44 as a diagnostic biomarker in patients with gastric cancer.
    Watanabe T; Okumura T; Hirano K; Yamaguchi T; Sekine S; Nagata T; Tsukada K
    Oncol Lett; 2017 Jan; 13(1):281-288. PubMed ID: 28123556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
    Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
    BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating Cancer Stem Cells Expressing EpCAM/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living Donor Liver Transplantation.
    Hwang HS; Yoo JE; Han DH; Choi JS; Lee JG; Joo DJ; Kim MS; Kim SI; Choi GH; Park YN
    Gut Liver; 2022 May; 16(3):443-455. PubMed ID: 34737243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.
    Julich-Haertel H; Urban SK; Krawczyk M; Willms A; Jankowski K; Patkowski W; Kruk B; Krasnodębski M; Ligocka J; Schwab R; Richardsen I; Schaaf S; Klein A; Gehlert S; Sänger H; Casper M; Banales JM; Schuppan D; Milkiewicz P; Lammert F; Krawczyk M; Lukacs-Kornek V; Kornek M
    J Hepatol; 2017 Aug; 67(2):282-292. PubMed ID: 28267620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research.
    Grover PK; Cummins AG; Price TJ; Roberts-Thomson IC; Hardingham JE
    Ann Oncol; 2014 Aug; 25(8):1506-16. PubMed ID: 24651410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer.
    Hyun KA; Koo GB; Han H; Sohn J; Choi W; Kim SI; Jung HI; Kim YS
    Oncotarget; 2016 Apr; 7(17):24677-87. PubMed ID: 27013581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual-Aptamer-Targeted Immunomagnetic Nanoparticles to Accurately Explore the Correlations between Circulating Tumor Cells and Gastric Cancer.
    Li C; Yang S; Li R; Gong S; Huang M; Sun Y; Xiong G; Wu D; Ji M; Chen Y; Gao C; Yu Y
    ACS Appl Mater Interfaces; 2022 Feb; 14(6):7646-7658. PubMed ID: 35104098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of EpCAM
    Liu M; Di J; Liu Y; Su Z; Jiang B; Wang Z; Su X
    Cancer Biol Ther; 2018; 19(10):939-947. PubMed ID: 29580161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Workflow to Enrich and Isolate Patient-Matched EpCAM
    Lampignano R; Yang L; Neumann MHD; Franken A; Fehm T; Niederacher D; Neubauer H
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28858218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma.
    Ji J; Zheng X; Forgues M; Yamashita T; Wauthier EL; Reid LM; Wen X; Song Y; Wei JS; Khan J; Thorgeirsson SS; Wang XW
    Hepatology; 2015 Sep; 62(3):829-40. PubMed ID: 25953724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Onstenk W; Kraan J; Mostert B; Timmermans MM; Charehbili A; Smit VT; Kroep JR; Nortier JW; van de Ven S; Heijns JB; Kessels LW; van Laarhoven HW; Bos MM; van de Velde CJ; Gratama JW; Sieuwerts AM; Martens JW; Foekens JA; Sleijfer S
    Mol Cancer Ther; 2015 Mar; 14(3):821-7. PubMed ID: 25552367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application.
    Yin J; Wang Y; Yin H; Chen W; Jin G; Ma H; Dai J; Chen J; Jiang Y; Wang H; Liu Z; Hu Z; Shen H
    PLoS One; 2015; 10(8):e0137076. PubMed ID: 26317979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
    Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
    Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation.
    Gabriel MT; Calleja LR; Chalopin A; Ory B; Heymann D
    Clin Chem; 2016 Apr; 62(4):571-81. PubMed ID: 26896446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical value of classified detection of circulating tumor cells in peripheral blood of NSCLC patients].
    Yin HL; Yin J; Chen LW; Li N; Liu ZA; Hu ZB; Shen HB
    Zhonghua Zhong Liu Za Zhi; 2016 Sep; 38(9):677-81. PubMed ID: 27647400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update.
    Eyvazi S; Farajnia S; Dastmalchi S; Kanipour F; Zarredar H; Bandehpour M
    Curr Cancer Drug Targets; 2018; 18(9):857-868. PubMed ID: 29295696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
    Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
    Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of novel markers that outperform EpCAM in quantifying circulating tumor cells.
    Kim MJ; Choi NY; Lee EK; Kang MS
    Cell Oncol (Dordr); 2014 Aug; 37(4):235-43. PubMed ID: 25001871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the EpCAM (CD326) in prostate cancer metastasis and progression.
    Ni J; Cozzi PJ; Duan W; Shigdar S; Graham PH; John KH; Li Y
    Cancer Metastasis Rev; 2012 Dec; 31(3-4):779-91. PubMed ID: 22718399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.